Retrospective Multi-Center Study to Compare Perioperative Outcomes for Robotic-assisted Lobectomy With Those Associated With VATS and Open Lobectomy for Lung Cancer

Study summary

The main objective of this study is to evaluate and compare peri-operative outcomes of lobectomy compare with different approaches. The study aims to include patients with stage IA, IB, IIA, IIB and IIIA lung cancer that underwent lobectomy via robotic-assisted, VATS and open approach.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedRobotic-assisted lobectomy using da Vinci Surgical System and VATS (video assisted thoracic surgery)

Plus 1 other study approaches.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 3, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Intuitive Surgical

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Intuitive Surgical
Interventions being studied: Procedure: Robotic-assisted lobectomy using da Vinci Surgical System; Procedure: VATS (video assisted thoracic surgery); Procedure: Open lobectomy

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Surgery→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Subject is 18 years or older
Subject who has undergone elective robotic-assisted, VATS or open lobectomy for clinically diagnosed primary stage IA, IB, IIA, IIB and IIIA lung cancer, with or without neo-adjuvant therapy

Reasons someone may not be able to joinExclusion criteria

Subject with stage IIIB lung cancer
Subject who received lobectomy as an emergent procedure
Subjects who received lobectomy for metastatic cancer

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

BaylorScott&WhiteDallas, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 3, 2021. Always confirm current availability with the study team.

View original record ↗